What does the evidence say about THC and CBD for treating multiple sclerosis?
A critical review found moderate evidence supporting THC:CBD combinations for MS-related spasticity and pain, but evidence for other MS symptoms remains limited.
Quick Facts
What This Study Found
The review found the strongest evidence for nabiximols (Sativex, a 1:1 THC:CBD oromucosal spray) in reducing spasticity and neuropathic pain in MS patients. Evidence for effects on tremor, bladder dysfunction, and sleep was less consistent.
Key Numbers
Nabiximols (Sativex) is approved in over 25 countries for MS spasticity; clinical trials typically showed 20-30% improvement in spasticity scores.
How They Did This
Critical narrative review synthesizing clinical trial data, observational studies, and regulatory submissions for cannabinoid-based treatments in multiple sclerosis.
Why This Research Matters
Multiple sclerosis affects millions worldwide, and spasticity is one of its most debilitating symptoms. This review consolidates what is known about cannabinoid treatments to help clarify where the evidence is strongest.
The Bigger Picture
Nabiximols represents one of the most successful translations of cannabinoid science into approved medicine. Its targeted use for MS spasticity shows how specific cannabinoid formulations may work best for specific symptoms rather than as broad treatments.
What This Study Doesn't Tell Us
Narrative review format (not systematic); heterogeneity in how MS symptoms are measured across studies; many trials had small sample sizes.
Questions This Raises
- ?Could different THC:CBD ratios be more effective for specific MS symptoms?
- ?What are the long-term effects of sustained cannabinoid use in MS patients?
Trust & Context
- Key Stat:
- Nabiximols approved in 25+ countries for MS spasticity
- Evidence Grade:
- Moderate: synthesizes clinical trial data but uses narrative review format rather than systematic methodology.
- Study Age:
- Published 2016.
- Original Title:
- A Critical Review of the Role of the Cannabinoid Compounds Δ9-Tetrahydrocannabinol (Δ9-THC) and Cannabidiol (CBD) and their Combination in Multiple Sclerosis Treatment.
- Published In:
- Molecules (Basel, Switzerland), 25(21) (2020)
- Authors:
- Jones, Éamon, Vlachou, Styliani(2)
- Database ID:
- RTHC-02636
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Which MS symptoms respond best to cannabinoid treatment?
Spasticity and neuropathic pain have the strongest evidence, primarily using nabiximols (a 1:1 THC:CBD oromucosal spray marketed as Sativex).
Is Sativex widely available?
Nabiximols (Sativex) is approved in over 25 countries for MS-related spasticity, though availability and insurance coverage vary by region.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-02636APA
Jones, Éamon; Vlachou, Styliani. (2020). A Critical Review of the Role of the Cannabinoid Compounds Δ9-Tetrahydrocannabinol (Δ9-THC) and Cannabidiol (CBD) and their Combination in Multiple Sclerosis Treatment.. Molecules (Basel, Switzerland), 25(21). https://doi.org/10.3390/molecules25214930
MLA
Jones, Éamon, et al. "A Critical Review of the Role of the Cannabinoid Compounds Δ9-Tetrahydrocannabinol (Δ9-THC) and Cannabidiol (CBD) and their Combination in Multiple Sclerosis Treatment.." Molecules (Basel, 2020. https://doi.org/10.3390/molecules25214930
RethinkTHC
RethinkTHC Research Database. "A Critical Review of the Role of the Cannabinoid Compounds Δ..." RTHC-02636. Retrieved from https://rethinkthc.com/research/jones-2020-a-critical-review-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.